WallStreetZenWallStreetZen

NASDAQ: ALLO
Allogene Therapeutics Inc Stock Ownership - Who owns Allogene Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Allogene Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Benjamin Machinas BeneskiSVP Chief Technical Officer2025-11-17786$1.22
$958.92Sell
Geoffrey M. ParkerCHIEF FINANCIAL OFFICER2025-10-2136,744$1.26
$46.15kSell
Deborah M. MessemerDirector2025-06-1036,885$1.42
$52.38kSell
Annie YoshiyamaSVP Finance2025-04-219,601$1.41
$13.54kSell
Benjamin Machinas BeneskiSVP Chief Technical Officer2025-03-145,488$1.98
$10.84kSell
David D. ChangPresident and CEO2025-03-1446,668$1.96
$91.47kSell
Deborah M. MessemerDirector2025-02-1813,313$2.43
$32.35kSell
David D. ChangPresident and CEO2025-02-0346,003$1.68
$77.29kSell
Zachary RobertsEVP of RD2025-02-0318,832$1.70
$32.01kSell
Geoffrey M. ParkerCHIEF FINANCIAL OFFICER2025-02-034,361$1.73
$7.54kSell

1 of 2

ALLO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALLO insiders and whales buy or sell their stock.

ALLO Shareholders

What type of owners hold Allogene Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Pfizer Inc9.80%22,032,040$32.61MInsider
Pfizer Inc9.80%22,032,040$32.61MInstitution
Tpg Group Holdings Sbs Advisors Inc8.33%18,716,306$27.70MInsider
Tpg GP A LLC8.33%18,716,306$27.70MInsider
Tpg GP A LLC8.33%18,716,306$27.70MInstitution
Blackrock Inc7.79%17,514,674$25.92MInstitution
Citadel Advisors LLC6.22%13,971,557$20.68MInstitution
Vanguard Group Inc4.01%9,020,770$13.35MInstitution
Primecap Management Co3.15%7,079,308$10.48MInstitution
David D. Chang2.88%6,477,677$9.59MInsider

1 of 3

ALLO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALLO67.48%32.52%Net SellingNet Selling
NMRA23.65%76.35%Net BuyingNet Buying
LRMR57.15%42.85%Net Buying
AVTX15.86%84.14%Net SellingNet Selling
NBY0.10%99.90%Net Buying
View Top Biotech Stocks

Allogene Therapeutics Stock Ownership FAQ

Who owns Allogene Therapeutics?

Allogene Therapeutics (NASDAQ: ALLO) is owned by 72.14% institutional shareholders, 34.77% Allogene Therapeutics insiders, and 0.00% retail investors. Pfizer Inc is the largest individual Allogene Therapeutics shareholder, owning 22.03M shares representing 9.80% of the company. Pfizer Inc's Allogene Therapeutics shares are currently valued at $34.15M.

If you're new to stock investing, here's how to buy Allogene Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.